{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T23:33:13Z","timestamp":1793403193217,"version":"4.5.0"},"reference-count":92,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jad.2025.119952","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T16:51:22Z","timestamp":1752857482000},"page":"119952","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Mapping psilocybin therapy: A systematic review of therapeutic frameworks, adaptations, and standardization across contemporary clinical trials"],"prefix":"10.1016","volume":"391","author":[{"given":"Mary E.","family":"Kittur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Almendra","family":"Burgos M.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett D.M.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel M.","family":"Blumberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit H.","family":"Mulsant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Rosenblat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Ishrat","family":"Husain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2025.119952_bb0005","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1001\/jamapsychiatry.2023.0549","article-title":"Emerging challenges for psychedelic therapy","volume":"80","author":"Aday","year":"2023","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jad.2025.119952_bb0010","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1007\/s00213-024-06620-x","article-title":"Psychedelic-assisted psychotherapy: where is the psychotherapy research?","volume":"241","author":"Aday","year":"2024","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jad.2025.119952_bb0015","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1001\/jamaoncol.2023.0351","article-title":"Assessment of psilocybin therapy for patients with Cancer and major depression disorder","volume":"9","author":"Agrawal","year":"2023","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.jad.2025.119952_bb0020","series-title":"Professional Practice Guidelines for Psychedelic-Assisted Therapy","author":"American Psychedelic Practictioners Association BrainFutures","year":"2023"},{"key":"10.1016\/j.jad.2025.119952_bb0025","series-title":"Diagnostic and statistical manual of mental disorders, Fifth Edition. ed. American Psychiatric Association","year":"2013"},{"key":"10.1016\/j.jad.2025.119952_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100538","article-title":"Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: an open-label safety and feasibility pilot study","volume":"27","author":"Anderson","year":"2020","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jad.2025.119952_bb0035","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/jat\/22.1.45","article-title":"Presence of Phenylethylamine in hallucinogenic Psilocybe mushroom: possible role in adverse reactions","volume":"22","author":"Beck","year":"1998","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.jad.2025.119952_bb0040","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.neuropharm.2018.02.018","article-title":"Psychedelics: where we are now, why we got here, what we must do","volume":"142","author":"Belouin","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jad.2025.119952_bb0045","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1177\/0022167816673493","article-title":"Development of a psychotherapeutic model for psilocybin-assisted treatment of alcoholism","volume":"57","author":"Bogenschutz","year":"2017","journal-title":"J. Humanist. Psychol."},{"key":"10.1016\/j.jad.2025.119952_bb0050","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/0269881114565144","article-title":"Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study","volume":"29","author":"Bogenschutz","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2025.119952_bb0055","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","article-title":"Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial","volume":"79","author":"Bogenschutz","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jad.2025.119952_bb0060","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1200\/JCO.2014.57.2198","article-title":"Meaning-centered group psychotherapy: an effective intervention for improving psychological well-being in patients with advanced cancer","volume":"33","author":"Breitbart","year":"2015","journal-title":"JCO"},{"key":"10.1016\/j.jad.2025.119952_bb0065","article-title":"Models of psychedelic-assisted psychotherapy: a contemporary assessment and an introduction to EMBARK, a Transdiagnostic","volume":"13","author":"Brennan","year":"2022","journal-title":"Trans-Drug Model. Front. Psychol."},{"key":"10.1016\/j.jad.2025.119952_bb0070","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of psilocybin versus escitalopram for depression","volume":"384","author":"Carhart-Harris","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jad.2025.119952_bb0075","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study","volume":"3","author":"Carhart-Harris","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.jad.2025.119952_bb0080","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00213-017-4771-x","article-title":"Psilocybin with psychological support for treatment-resistant depression: six-month follow-up","volume":"235","author":"Carhart-Harris","year":"2018","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jad.2025.119952_bb0085","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyg.2022.887255","article-title":"Psychedelic-assisted psychotherapy\u2014a systematic review of associated psychological interventions","volume":"13","author":"Cavarra","year":"2022","journal-title":"Front. Psychol."},{"key":"10.1016\/j.jad.2025.119952_bb0090","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jpsychires.2024.05.051","article-title":"Protocols and practices in psilocybin assisted psychotherapy for depression: a systematic review","volume":"176","author":"Chisamore","year":"2024","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jad.2025.119952_bb0095","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1177\/082585970402000303","article-title":"Dignity and psychotherapeutic considerations in end-of-life care","volume":"20","author":"Chochinov","year":"2004","journal-title":"J. Palliat. Care"},{"key":"10.1016\/j.jad.2025.119952_bb0100","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1001\/archpsyc.58.5.494","article-title":"Supportive-expressive group therapy and distress in patients with metastatic breast Cancer: a randomized clinical intervention trial","volume":"58","author":"Classen","year":"2001","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2025.119952_bb0105","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/(SICI)1099-1611(199909\/10)8:5<395::AID-PON408>3.0.CO;2-B","article-title":"Re-creating your life: a spiritual\/psychotherapeutic intervention for people diagnosed with cancer","volume":"8","author":"Cole","year":"1999","journal-title":"Psycho-Oncology"},{"key":"10.1016\/j.jad.2025.119952_bb0110","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial","volume":"78","author":"Davis","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jad.2025.119952_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2024.110280","article-title":"Concurrent stress modulates the acute and post-acute effects of psilocybin in a sex-dependent manner","volume":"266","author":"Farinha-Ferreira","year":"2025","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jad.2025.119952_bb0120","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1080\/09540261.2018.1486289","article-title":"Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions","volume":"30","author":"Garcia-Romeu","year":"2018","journal-title":"Int. Rev. Psychiatry"},{"key":"10.1016\/j.jad.2025.119952_bb0125","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1111\/jnc.16017","article-title":"Psilocybin as a lead candidate molecule in preclinical therapeutic studies of psychiatric disorders: a systematic review","volume":"168","author":"Gattuso","year":"2024","journal-title":"J. Neurochem."},{"key":"10.1016\/j.jad.2025.119952_bb0130","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S2215-0366(21)00395-3","article-title":"Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990\u20132019: a systematic analysis for the global burden of disease study 2019","volume":"9","year":"2022","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.jad.2025.119952_bb0135","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression","volume":"387","author":"Goodwin","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jad.2025.119952_bb0140","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1038\/s41386-023-01648-7","article-title":"Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication","volume":"48","author":"Goodwin","year":"2023","journal-title":"Neuropsychopharmacol"},{"key":"10.1016\/j.jad.2025.119952_bb0145","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1176\/appi.ajp.20221043","article-title":"Must psilocybin always \u201cassist psychotherapy\u201d?","volume":"181","author":"Goodwin","year":"2024","journal-title":"AJP"},{"key":"10.1016\/j.jad.2025.119952_bb0150","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","article-title":"Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance","volume":"187","author":"Griffiths","year":"2006","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jad.2025.119952_bb0155","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2025.119952_bb0160","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","article-title":"Pilot study of psilocybin treatment for anxiety in patients with advanced-stage Cancer","volume":"68","author":"Grob","year":"2011","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2025.119952_bb0165","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1177\/1363461520983684","article-title":"Psychedelics, placebo effects, and set and setting: insights from common factors theory of psychotherapy","volume":"59","author":"Gukasyan","year":"2022","journal-title":"Transcult. Psychiatry"},{"key":"10.1016\/j.jad.2025.119952_bb0170","author":"Guss","year":"2020","journal-title":"The Yale Manual for Psilocybin-Assisted Therapy of Depression (using Acceptance and Commitment Therapy as a Therapeutic Frame)."},{"key":"10.1016\/j.jad.2025.119952_bb0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/02791072.2021.2022254","article-title":"The psychedelic renaissance in clinical research: a bibliometric analysis of three decades of human studies with psychedelics","volume":"55","author":"Hadar","year":"2023","journal-title":"J. Psychoactive Drugs"},{"key":"10.1016\/j.jad.2025.119952_bb0180","doi-asserted-by":"crossref","first-page":"897","DOI":"10.3389\/fphar.2018.00897","article-title":"Predicting responses to psychedelics: a prospective study","volume":"9","author":"Haijen","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jad.2025.119952_bb0185","series-title":"ACT Made Simple: An Easy-to-Read Primer on Acceptance and Commitment Therapy","author":"Harris","year":"2009"},{"key":"10.1016\/j.jad.2025.119952_bb0190","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2018.00129","article-title":"The meaning-enhancing properties of psychedelics and their mediator role in psychedelic therapy, spirituality, and creativity","volume":"12","author":"Hartogsohn","year":"2018","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.jad.2025.119952_bb0195","series-title":"A Liberated Mind: The Essential Guide to ACT\u00a0: Transform your Thinking & Find Freedom from Stress, Anxiety, Depression & Addiction","author":"Hayes","year":"2019"},{"key":"10.1016\/j.jad.2025.119952_bb0200","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1007\/s10461-013-0441-0","article-title":"Supportive-expressive and coping group Teletherapies for HIV-infected older adults: a randomized clinical trial","volume":"17","author":"Heckman","year":"2013","journal-title":"AIDS Behav."},{"key":"10.1016\/j.jad.2025.119952_bb0205","article-title":"Nature-themed video intervention may improve cardiovascular safety of psilocybin-assisted therapy for alcohol use disorder","volume":"14","author":"Heinzerling","year":"2023","journal-title":"Front. Psych."},{"key":"10.1016\/j.jad.2025.119952_bb0210","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2022489118","article-title":"Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice","volume":"118","author":"Hesselgrave","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jad.2025.119952_bb0215","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1176\/appi.psychotherapy.20200055","article-title":"Systematized review of psychotherapeutic components of psilocybin-assisted psychotherapy","volume":"74","author":"Horton","year":"2021","journal-title":"APT"},{"key":"10.1016\/j.jad.2025.119952_bb0220","series-title":"Note for Guidance on Non-Clinical Safety Pharmacology Studies for Human Pharmaceuticals M3(R2)","author":"ICH","year":"2009"},{"key":"10.1016\/j.jad.2025.119952_bb0225","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/0269881108093587","article-title":"Human hallucinogen research: guidelines for safety","volume":"22","author":"Johnson","year":"2008","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2025.119952_bb0230","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1177\/0269881114548296","article-title":"Pilot study of the 5-HT 2A R agonist psilocybin in the treatment of tobacco addiction","volume":"28","author":"Johnson","year":"2014","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2025.119952_bb0235","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00213-017-4820-5","article-title":"The hidden therapist: evidence for a central role of music in psychedelic therapy","volume":"235","author":"Kaelen","year":"2018","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jad.2025.119952_bb0240","series-title":"Psycho-Oncology","first-page":"532","article-title":"Supportive-expressive and other forms of group psychotherapy in cancer care","author":"Kissane","year":"2015"},{"key":"10.1016\/j.jad.2025.119952_bb0245","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.1200\/JCO.2004.12.129","article-title":"Effect of cognitive-existential group therapy on survival in early-stage breast Cancer","volume":"22","author":"Kissane","year":"2004","journal-title":"JCO"},{"key":"10.1016\/j.jad.2025.119952_bb0250","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1177\/0269881119857204","article-title":"Microdosing psychedelics: more questions than answers? An overview and suggestions for future research","volume":"33","author":"Kuypers","year":"2019","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2025.119952_bb0255","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/00005053-196312000-00007","article-title":"Reactions to PSILOCYBJN administered in a supportive environment","volume":"137","author":"Leary","year":"1963","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.jad.2025.119952_bb0260","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1188\/06.ONF.291-302","article-title":"Meaning-making and psychological adjustment to Cancer: development of an intervention and pilot results","volume":"33","author":"Lee","year":"2006","journal-title":"Oncol. Nurs. Forum"},{"key":"10.1016\/j.jad.2025.119952_bb0265","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/wps.20941","article-title":"The efficacy of psychotherapies and pharmacotherapies for mental disorders in adults: an umbrella review and meta-analytic evaluation of recent meta-analyses","volume":"21","author":"Leichsenring","year":"2022","journal-title":"World Psychiatry"},{"key":"10.1016\/j.jad.2025.119952_bb0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1556\/2054.2022.00222","article-title":"Group format psychedelic-assisted therapy interventions: observations and impressions from the HOPE trial","volume":"7","author":"Lewis","year":"2023","journal-title":"JPS"},{"key":"10.1016\/j.jad.2025.119952_bb0275","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jpainsymman.2023.06.006","article-title":"HOPE: a pilot study of psilocybin enhanced group psychotherapy in patients with cancer","volume":"66","author":"Lewis","year":"2023","journal-title":"J. Pain Symptom Manag."},{"key":"10.1016\/j.jad.2025.119952_bb0280","doi-asserted-by":"crossref","first-page":"516","DOI":"10.15288\/jsad.2009.70.516","article-title":"Cognitive-behavioral treatment with adult alcohol and illicit drug users: a Meta-analysis of randomized controlled trials","volume":"70","author":"Magill","year":"2009","journal-title":"J. Stud. Alcohol Drugs"},{"key":"10.1016\/j.jad.2025.119952_bb0285","doi-asserted-by":"crossref","first-page":"7619","DOI":"10.1017\/S0033291723001411","article-title":"Cost-effectiveness of psilocybin-assisted therapy for severe depression: exploratory findings from a decision analytic model","volume":"53","author":"McCrone","year":"2023","journal-title":"Psychol. Med."},{"key":"10.1016\/j.jad.2025.119952_bb0290","series-title":"Motivational Interviewing: Helping People Change","author":"Miller","year":"2013"},{"key":"10.1016\/j.jad.2025.119952_bb0295","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/s41593-023-01316-5","article-title":"Psychedelics promote plasticity by directly binding to BDNF receptor TrkB","volume":"26","author":"Moliner","year":"2023","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.jad.2025.119952_bb0300","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.4088\/JCP.v67n1110","article-title":"Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder","volume":"67","author":"Moreno","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2025.119952_bb0305","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.788155","article-title":"Therapeutic Alliance and rapport modulate responses to psilocybin assisted therapy for depression","volume":"12","author":"Murphy","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jad.2025.119952_bb0310","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1080\/17512433.2021.1933434","article-title":"Blinding and expectancy confounds in psychedelic randomized controlled trials","volume":"14","author":"Muthukumaraswamy","year":"2021","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"10.1016\/j.jad.2025.119952_bb0315","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.22r14518","article-title":"Control conditions in randomized trials of psychedelics: an ACTTION systematic review","volume":"84","author":"Nayak","year":"2023","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2025.119952_bb0320","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1124\/pr.115.011478","article-title":"Psychedelics","volume":"68","author":"Nichols","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.jad.2025.119952_bb0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109257","article-title":"Psychedelics therapeutics: what we know, what we think, and what we need to research","volume":"223","author":"Nutt","year":"2023","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jad.2025.119952_bb0330","series-title":"A Manual for Motivational Enhancement Treatment (MET) to Improve Treatment Engagement and Outcome in Subjects Seeking Treatment for Substance Abuse (Manual for Protocol 0004)","author":"Obert","year":"2000"},{"key":"10.1016\/j.jad.2025.119952_bb0335","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1556\/2054.2019.026","article-title":"Psilocybin for depression: considerations for clinical trial design","volume":"3","author":"O'Donnell","year":"2019","journal-title":"J. Psychedelics Stud."},{"key":"10.1016\/j.jad.2025.119952_bb0340","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1176\/appi.ajp.20230661","article-title":"Misinterpretations and omissions: a critical response to Goodwin and colleagues' commentary on psilocybin-assisted therapy","volume":"181","author":"O'Donnell","year":"2024","journal-title":"AJP"},{"key":"10.1016\/j.jad.2025.119952_bb0345","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jad.2025.119952_bb0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.120096","article-title":"Psilocybin-assisted psychotherapy for depression: emerging research on a psychedelic compound with a rich history","volume":"434","author":"Pearson","year":"2022","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jad.2025.119952_bb0355","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1038\/s41591-023-02455-9","article-title":"Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study","volume":"29","author":"Peck","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.jad.2025.119952_bb0360","doi-asserted-by":"crossref","first-page":"170","DOI":"10.15288\/jsas.2005.s15.170","article-title":"A structured approach to medical management: a psychosocial intervention to support pharmacotherapy in the treatment of alcohol dependence","author":"Pettinati","year":"2005","journal-title":"J. Stud. Alcohol Suppl"},{"key":"10.1016\/j.jad.2025.119952_bb0365","series-title":"Disruptive Psychopharmacology, Current Topics in Behavioral Neurosciences","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/7854_2021_266","article-title":"Foundations for training psychedelic therapists","author":"Phelps","year":"2021"},{"key":"10.1016\/j.jad.2025.119952_bb0370","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jama.2023.14530","article-title":"Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial","volume":"330","author":"Raison","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jad.2025.119952_bb0375","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1176\/appi.ajp.2019.19010035","article-title":"Psychedelics and psychedelic-assisted psychotherapy","volume":"177","author":"Reiff","year":"2020","journal-title":"AJP"},{"key":"10.1016\/j.jad.2025.119952_bb0380","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1080\/02791072.2018.1535149","article-title":"How to change your mind: what the new science of psychedelics teaches us about consciousness, dying, addiction, depression, and transcendence","volume":"50","author":"Rhead","year":"2018","journal-title":"J. Psychoactive Drugs"},{"key":"10.1016\/j.jad.2025.119952_bb0385","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial","volume":"30","author":"Ross","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2025.119952_bb0390","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1177\/0269881116679368","article-title":"Psychedelics in the treatment of unipolar mood disorders: a systematic review","volume":"30","author":"Rucker","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2025.119952_bb0395","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jpsychires.2023.03.031","article-title":"Pilot study of single-dose psilocybin for serotonin reuptake inhibitor-resistant body dysmorphic disorder","volume":"161","author":"Schneier","year":"2023","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jad.2025.119952_bb0400","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/s41386-024-01794-6","article-title":"Antidepressant-like effects of psychedelics in a chronic despair mouse model: is the 5-HT2A receptor the unique player?","volume":"49","author":"Sekssaoui","year":"2024","journal-title":"Neuropsychopharmacol"},{"key":"10.1016\/j.jad.2025.119952_bb0405","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jad.2022.11.046","article-title":"Psilocybin-assisted therapy improves psycho-social-spiritual well-being in cancer patients","volume":"323","author":"Shnayder","year":"2023","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2025.119952_bb0410","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jcbs.2019.11.002","article-title":"Psilocybin-assisted therapy of major depressive disorder using acceptance and commitment therapy as a therapeutic frame","volume":"15","author":"Sloshower","year":"2020","journal-title":"J. Contextual Behav. Sci."},{"key":"10.1016\/j.jad.2025.119952_bb0415","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1177\/02698811231154852","article-title":"Psilocybin-assisted therapy for major depressive disorder: an exploratory placebo-controlled, fixed-order trial","volume":"37","author":"Sloshower","year":"2023","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2025.119952_bb0420","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030800","article-title":"Prediction of psilocybin response in healthy volunteers","volume":"7","author":"Studerus","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jad.2025.119952_bb0425","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/heapro\/16.3.255","article-title":"Effectiveness of a cognitive behaviour therapy self-help programme for smokers in London, UK","volume":"16","author":"Sykes","year":"2001","journal-title":"Health Promot. Int."},{"key":"10.1016\/j.jad.2025.119952_bb0430","article-title":"Development and evaluation of a therapist training program for psilocybin therapy for treatment-resistant depression in clinical research","volume":"12","author":"Tai","year":"2021","journal-title":"Front. Psych."},{"key":"10.1016\/j.jad.2025.119952_bb0435","author":"U.S. Food and Drug Administration"},{"key":"10.1016\/j.jad.2025.119952_bb0440","series-title":"Covidence Systematic Review Software","author":"Veritas Health","year":"2023"},{"key":"10.1016\/j.jad.2025.119952_bb0445","article-title":"Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial","volume":"56","author":"Von Rotz","year":"2023","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.jad.2025.119952_bb0450","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jcbs.2019.12.004","article-title":"The use of the psychological flexibility model to support psychedelic assisted therapy","volume":"15","author":"Watts","year":"2020","journal-title":"J. Contextual Behav. Sci."},{"key":"10.1016\/j.jad.2025.119952_bb0455","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0005-7967(95)00084-4","article-title":"Manual-based treatments: the clinical application of research findings","volume":"34","author":"Wilson","year":"1996","journal-title":"Behav. Res. Ther."},{"key":"10.1016\/j.jad.2025.119952_bb0460","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1111\/j.1360-0443.2008.02348.x","article-title":"A randomized trial of short psychotherapy versus sustained-release bupropion for smoking cessation","volume":"103","author":"Zernig","year":"2008","journal-title":"Addiction"}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032725013941?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032725013941?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T05:07:37Z","timestamp":1779858457000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032725013941"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":92,"alternative-id":["S0165032725013941"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2025.119952","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mapping psilocybin therapy: A systematic review of therapeutic frameworks, adaptations, and standardization across contemporary clinical trials","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2025.119952","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"119952"}}